These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

275 related items for PubMed ID: 34382671

  • 21. 99mTc-MIP-1404 SPECT/CT for Patients With Metastatic Prostate Cancer: Interobserver and Intraobserver Variability in Treatment-Related Longitudinal Tracer Uptake Assessments of Prostate-Specific Membrane Antigen-Positive Lesions.
    Schmidkonz C, Atzinger A, Goetz TI, Beck M, Ritt P, Prante O, Kuwert T, Bäuerle T, Cordes M.
    Clin Nucl Med; 2020 Feb; 45(2):105-112. PubMed ID: 31876822
    [Abstract] [Full Text] [Related]

  • 22. Whole-Body Integrated [68Ga]PSMA-11-PET/MR Imaging in Patients with Recurrent Prostate Cancer: Comparison with Whole-Body PET/CT as the Standard of Reference.
    Guberina N, Hetkamp P, Ruebben H, Fendler W, Grueneisen J, Suntharalingam S, Kirchner J, Puellen L, Harke N, Radtke JP, Umutlu L, Hadaschik BA, Herrmann K, Forsting M, Wetter A.
    Mol Imaging Biol; 2020 Jun; 22(3):788-796. PubMed ID: 31482413
    [Abstract] [Full Text] [Related]

  • 23. 99mTc-MIP-1404 SPECT/CT for Assessment of Whole-Body Tumor Burden and Treatment Response in Patients With Biochemical Recurrence of Prostate Cancer.
    Schmidkonz C, Götz TI, Atzinger A, Ritt P, Prante O, Kuwert T, Bäuerle T, Goebell P, Cordes M.
    Clin Nucl Med; 2020 Aug; 45(8):e349-e357. PubMed ID: 32558706
    [Abstract] [Full Text] [Related]

  • 24. 68Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy.
    Ceci F, Castellucci P, Graziani T, Farolfi A, Fonti C, Lodi F, Fanti S.
    Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):31-39. PubMed ID: 30350010
    [Abstract] [Full Text] [Related]

  • 25. Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT/CT in prostate carcinoma: A comparative analysis with Ga-68 PSMA PET/CT.
    Lawal IO, Ankrah AO, Mokgoro NP, Vorster M, Maes A, Sathekge MM.
    Prostate; 2017 Aug; 77(11):1205-1212. PubMed ID: 28649735
    [Abstract] [Full Text] [Related]

  • 26. Biodistribution of [(68)Ga]PSMA-HBED-CC in Patients with Prostate Cancer: Characterization of Uptake in Normal Organs and Tumour Lesions.
    Prasad V, Steffen IG, Diederichs G, Makowski MR, Wust P, Brenner W.
    Mol Imaging Biol; 2016 Jun; 18(3):428-36. PubMed ID: 27038316
    [Abstract] [Full Text] [Related]

  • 27. Efficacy of early imaging with 68Ga-PSMA-I&T in the discrimination of pelvic lesions in prostate cancer patients.
    Özülker F.
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019 Jun; 38(2):100-105. PubMed ID: 30514659
    [Abstract] [Full Text] [Related]

  • 28. 68Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients.
    Caroli P, Sandler I, Matteucci F, De Giorgi U, Uccelli L, Celli M, Foca F, Barone D, Romeo A, Sarnelli A, Paganelli G.
    Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2035-2044. PubMed ID: 29922948
    [Abstract] [Full Text] [Related]

  • 29. An Analysis of the Diagnostic Performance of Tc-99m PSMA SSPECT/CT in Biochemically Recurrent Prostate Cancer Compared with Ga-68 PSMA PET/CT: A Single-center, Prospective Study.
    Ora M, Saini VK, Dixit M, Singh UP, Gambhir S.
    Indian J Nucl Med; 2024 Nov; 39(3):170-176. PubMed ID: 39291065
    [Abstract] [Full Text] [Related]

  • 30. Intraindividual Comparison of 99mTc-Methylene Diphosphonate and Prostate-Specific Membrane Antigen Ligand 99mTc-MIP-1427 in Patients with Osseous Metastasized Prostate Cancer.
    Rathke H, Afshar-Oromieh A, Giesel FL, Kremer C, Flechsig P, Haufe S, Mier W, Holland-Letz T, De Bucourt M, Armor T, Babich JW, Haberkorn U, Kratochwil C.
    J Nucl Med; 2018 Sep; 59(9):1373-1379. PubMed ID: 29371410
    [Abstract] [Full Text] [Related]

  • 31. [68Ga]Ga-P16-093 as a PSMA-Targeted PET Radiopharmaceutical for Detection of Cancer: Initial Evaluation and Comparison with [68Ga]Ga-PSMA-11 in Prostate Cancer Patients Presenting with Biochemical Recurrence.
    Green MA, Hutchins GD, Bahler CD, Tann M, Mathias CJ, Territo W, Sims J, Polson H, Alexoff D, Eckelman WC, Kung HF, Fletcher JW.
    Mol Imaging Biol; 2020 Jun; 22(3):752-763. PubMed ID: 31429050
    [Abstract] [Full Text] [Related]

  • 32. Efficacy, Predictive Factors, and Prediction Nomograms for 68Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy.
    Rauscher I, Düwel C, Haller B, Rischpler C, Heck MM, Gschwend JE, Schwaiger M, Maurer T, Eiber M.
    Eur Urol; 2018 May; 73(5):656-661. PubMed ID: 29358059
    [Abstract] [Full Text] [Related]

  • 33. Association between 99mTc-PSMA SPECT/CT imaging and prostate-specific antigen (PSA) and alkaline phosphatase (ALP) levels post-endocrine therapy in patients with prostate cancer and bone metastases.
    Ruan X, Gao Y.
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2024 May; 43(6):500054. PubMed ID: 39260798
    [Abstract] [Full Text] [Related]

  • 34. 99mTc-PSMA SPECT/CT Versus 68Ga-PSMA PET/CT in the Evaluation of Metastatic Prostate Cancer.
    Fallahi B, Khademi N, Karamzade-Ziarati N, Fard-Esfahani A, Emami-Ardekani A, Farzanefar S, Eftekhari M, Beiki D.
    Clin Nucl Med; 2021 Feb 01; 46(2):e68-e74. PubMed ID: 33234922
    [Abstract] [Full Text] [Related]

  • 35. Comparison of hybrid 68Ga-PSMA-PET/CT and 99mTc-DPD-SPECT/CT for the detection of bone metastases in prostate cancer patients: Additional value of morphologic information from low dose CT.
    Janssen JC, Meißner S, Woythal N, Prasad V, Brenner W, Diederichs G, Hamm B, Makowski MR.
    Eur Radiol; 2018 Feb 01; 28(2):610-619. PubMed ID: 28779400
    [Abstract] [Full Text] [Related]

  • 36. 68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning.
    Calais J, Czernin J, Cao M, Kishan AU, Hegde JV, Shaverdian N, Sandler K, Chu FI, King CR, Steinberg ML, Rauscher I, Schmidt-Hegemann NS, Poeppel T, Hetkamp P, Ceci F, Herrmann K, Fendler WP, Eiber M, Nickols NG.
    J Nucl Med; 2018 Feb 01; 59(2):230-237. PubMed ID: 29123013
    [Abstract] [Full Text] [Related]

  • 37. The usefulness of 99mTc-tetrofosmin SPECT in the detection of lung metastases from extrapulmonary primary tumors.
    Spanu A, Solinas ME, Farris A, Arru A, Chessa F, Madeddu G, Falchi A, Madeddu G.
    Radiol Med; 2004 Feb 01; 107(1-2):113-27. PubMed ID: 15031703
    [Abstract] [Full Text] [Related]

  • 38. Clinical impact of 68 Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: preliminary analysis of a multidisciplinary approach.
    Albisinni S, Artigas C, Aoun F, Biaou I, Grosman J, Gil T, Hawaux E, Limani K, Otte FX, Peltier A, Sideris S, Sirtaine N, Flamen P, van Velthoven R.
    BJU Int; 2017 Aug 01; 120(2):197-203. PubMed ID: 27981732
    [Abstract] [Full Text] [Related]

  • 39. ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients.
    Elgamal AA, Troychak MJ, Murphy GP.
    Prostate; 1998 Dec 01; 37(4):261-9. PubMed ID: 9831223
    [Abstract] [Full Text] [Related]

  • 40. PSA-stratified detection rates for [68Ga]THP-PSMA, a novel probe for rapid kit-based 68Ga-labeling and PET imaging, in patients with biochemical recurrence after primary therapy for prostate cancer.
    Derlin T, Schmuck S, Juhl C, Zörgiebel J, Schneefeld SM, Walte ACA, Hueper K, von Klot CA, Henkenberens C, Christiansen H, Thackeray JT, Ross TL, Bengel FM.
    Eur J Nucl Med Mol Imaging; 2018 Jun 01; 45(6):913-922. PubMed ID: 29308527
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.